Almac Diagnostics is a stratified medicine company specialising in biomarker driven clinical trials. Our diagnostic experience spans oncology, immunology, CNS and infective diseases.
Our global laboratories offer tailored solutions from discovery to commercialisation:
• Biomarker discovery
• Custom assay development & validation
• DNA and RNA panel options for basket & umbrella trials
• Flexible CDx development & commercialisation
• Expert regulatory support
• Bioinformatics & software development
claraT Gene Expression Report
Our clinical trial diagnostic solutions from Discovery to Commercialisation
Maximise the understanding of your RNA data set
State of the art Global laboratories: UK, USA and China
Discover more about Almac Diagnostics
Almac Diagnostics Testimonials
“Your Project Managers have been tremendous support for all of the ups and downs with our Drug Programme. It may seem a small thing but it was terrific to feel as though they were allies rather than adversaries as we worked together. Their hard work has garnered my deep gratitude and more importantly an excellent reputation for Almac within our Company. Reflecting on how adaptable they were to all of the challenges we faced made it very easy to recommend that we partner with Almac for upcoming work ………. your Project Managers definitely deserve to be commended for all that they’ve done.”
Global Pharma Company
We started using Almac Diagnostics because the lab that had been running our assay for 5 years was no longer going to support our assay. I worked very well with this other lab and was concerned about having to change. However, Almac Diagnostics made this transition very easy. It was a pleasurable experience and I hope I get the chance to work with Almac Diagnostics again.
I just wanted to take a moment and thank you all and the extended Almac Diagnostics team for an awesome job in completing the IDE submission in record time. At times it looked really challenging, unrealistic and too cumbersome a process but the team did a great job despite all the odds.